Elan (ELN), Novartis (NVS) Tick Higher on PDUFA Extension for Biogen's (BIIB) MS PillBG-12
Tweet
Share
E-mailGet Alerts ELN Hot Sheet
Join SI Premium – FREE
Elan Corp. (NYSE: ELN) and Novartis (NYSE: NVS) shares are ticking higher following the FDA extending the initial PDUFA date for its review of the New Drug Application (NDA) for the marketing approval of Biogen Idec's (Nasdaq: BIIB) BG-12 (dimethyl fumarate).
BG-12 would compete with Biogen/Elan's Tysabri, Teva's (Nasdaq: TEVA) Copaxone, Sanofi's (NYSE: SNY) Aubagio, and Novartis' Gilenya.
BG-12 would compete with Biogen/Elan's Tysabri, Teva's (Nasdaq: TEVA) Copaxone, Sanofi's (NYSE: SNY) Aubagio, and Novartis' Gilenya.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- FDA grants fast track status to Rein Therapeutics drug for lung fibrosis
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
